Navigation Links
ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
Date:2/11/2009

- Conference Call to Discuss Results to Be Held at 9:00 A.M. -

EXTON, Pa., Feb. 11 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) fourth quarter and year end financial results for 2008 are expected to be released on Tuesday, February 24, 2009 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2008 fourth quarter and full year financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until March 16, 2009. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
2. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
3. ViroPharma Provides Update on Vancocin(R)
4. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
5. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
6. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
7. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
8. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
9. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
10. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
11. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... St. Joseph Medical ... health information exchange, which enables physicians at SJMC’s two hospital campuses, downtown and ... participating organizations in the exchange. SJMC’s membership in the health information exchange underscores ...
(Date:5/31/2016)... Beach, Florida (PRWEB) , ... May 31, 2016 ... ... to Jay Butch of CertainTeed Corporation, he knew it was something that contractors ... as state-of-the-art and cutting-edge as it gets,” says Butch, CertainTeed’s Director of Contractor ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... commercial molecular diagnostics device that enables unprecedented portability and convenience. , The Cube ... four inches cubed in size, the Cube fits easily into any space, whether ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... Like jewels ... 2,000 clients already know – London is home to Ontario’s leading day spa and ... of visionary Fayez Tamba began with a unique concept to combine spa services with ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... and numeral energies can describe personality traits in humans. Using presidential candidate Donald ... their name and vitality. , “AstroNumerology is not about adding numbers up,” ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... Deutschland und GERMANTOWN, Maryland ... Referenzdatensatz von Horizon bestätigt nachgewiesene ... s   QIAGEN N.V. ... Standard: QIA) gab heute die Ergänzung seines ... und Verifizierungsdaten bekannt, die die bewährte Genauigkeit ...
(Date:5/31/2016)... , Germany and ... -- QIAGEN N.V. (NASDAQ: QGEN ... extensive package consisting of a quality control set and ... System, reinforcing the proven accuracy of its next-generation sequencing ... training for laboratories. QIAGEN has incorporated the Horizon Discovery ...
(Date:5/31/2016)... 31, 2016 Diplomat Pharmacy, Inc. (NYSE: ... conversation slated for June 7, 2016, to take a closer ... noon to 1 p.m. ET, will focus on a man ... the road to wellness. The event is ... patients and health care professionals, talking about triumphs and the ...
Breaking Medicine Technology: